Country for PR: United Kingdom
Contributor: PR Newswire Europe
Wednesday, September 21 2022 - 20:29
AsiaNet
Ivory Dentin Graft(TM), the First and Only Dentin Graft, Receives CE Mark
KEFAR SAVA, Israel, Sept. 21, 2022 /PRNewswire- AsiaNet/-

- Ivory Dentin Graft creates a new dentin category of graft substitutes for 
repair and augmentation of bone defects.

    Developed by Ivory Graft Ltd.[]https://ivorygraft.com/, the Ivory Dentin 
Graft(TM) is a new dentin graft. This graft material has been tailored for use 
in dental procedures based on the advantages of autologous dentin grafts, 
documented and proven in years of scientific research and publications. An 
active organic matrix, Ivory Dentin Graft retains the natural form of the 
sourced porcine dentin, as well as the protein matrix. Ivory Dentin Graft is CE 
marked (according to MDR 2017/745).

    Ivory Dentin Graft is sourced from natural dentin, without additives. 
Dentin's composition is very similar to bone, therefore its biological and 
physicomechanical properties make it an ideal grafting material.

    This unique dentin graft substitute has been clinically proven to support 
new hard tissue formation. A prospective, randomized, semi double-blinded with 
blinded assessments clinical study was conducted. The study compared subjects 
grafted with Ivory Dentin Graft (Investigational group) and subjects grafted 
with a porcine cortico-cancellous heterologous bone mix (Comparator group) for 
alveolar ridge preservation following tooth extraction. At 4 months 
post-procedure – the study demonstrated Ivory Dentin Graft's efficacy results: 
superior promoting of good interface between the host bone and graft material 
(85% vs 40%), and 50% more increase of new bone formation (60.75% vs 42.81% 
respectively). These two features are important for tissue regeneration and 
integration, that follow tooth extraction and grafting, and facilitate 
osteogenic activity.

    "We believe that Ivory Graft's patented technology for this new category of 
dentin grafts has the potential to revolutionize dental graft substitutes and 
clinical grafting materials in general" said Eyal Miller, CEO. "We look forward 
to exhibiting and meeting with leading clinicians at the European Congress of 
Osseointegration (EAO) in Geneva next week and invite you to visit our booth 
(D47). Ivory Graft has shifted phase from R&D to commercialization, and 
partnered with expert European commercial partners, to accelerate Ivory Dentin 
Graft's presence in the EU. We are currently in the final phases of 
establishing our Distributing Partners and Key Opinion Leaders' network, with 
world leading professionals."

    About Ivory Graft [http://www.ivorygraft.com/]

    Established in 2013, Ivory Graft Ltd. is focused on developing, 
manufacturing and marketing porcine dentin graft materials for the repair or 
augmentation of bone defects. Ivory Graft has developed a naturally sourced, 
bioresorbable dentin graft material with an active organic matrix. Ivory Dentin 
Graft is CE marked, and the regulatory process for FDA clearance is underway. 
Ivory Graft's plans for future products include orthopedic (spine) applications 
as well as additional dental devices. Privately held, Ivory Graft was founded 
and is funded by leading clinicians and industry leaders. Ivory Graft is 
located in central Israel, within the innovative and thriving medical and 
dental ecosystem.

    LinkedIn  [https://www.linkedin.com/company/ivory-graft-ltd/]

    Logo - https://mma.prnewswire.com/media/1901824/Ivory_Graft_Logo.jpg

 
    Source: Ivory Graft Ltd.
Translations

Japanese